Home › Funds › ARS Investment Partners, LLC › REGN

ARS Investment Partners, LLC position in REGN

REGENERON PHARMACEUTICALS · Health Care

ARS Investment Partners, LLC reported holding 44,514 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$33.8M, representing 1.52% of its reported portfolio and ranking #19 among its reported holdings. ARS Investment Partners, LLC has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)44.51K sh
Reported value held$33.75M
Portfolio Weight1.52%
First reportedQ1 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How ARS Investment Partners, LLC's REGN position evolved

ARS Investment Partners, LLC first disclosed a stake in REGN in Q1 2024 at 12,006 shares (US$11.6M). The position peaked in Q1 2026 at 45,270 shares, worth US$35.0M. Across 11 filings, ARS Investment Partners, LLC increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 44,514 shares valued at US$33.8M — a reduction of -970 shares quarter over quarter.. Notable position changes include a 46% trim in Q4 2024 (shares fell 11% over the following quarter), a 222% increase in Q2 2025 (shares rose 8% over the following quarter), a 38% increase in Q3 2025 (shares rose 36% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 12.01K $11.56M New
Q2 2024 11.88K $12.48M Reduce
Q3 2024 12.02K $12.64M Add
Q4 2024 6.48K $4.62M Reduce
Q1 2025 6.48K $4.61M Hold
Q2 2025 20.86K $10.95M Add
Q3 2025 28.77K $16.18M Add
Q4 2025 35.45K $27.36M Add
Q1 2026 45.27K $34.98M Add
Q2 2026 45.48K $28.36M Hold
Q3 2026 44.51K $33.75M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has ARS Investment Partners, LLC held REGN?

ARS Investment Partners, LLC has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is ARS Investment Partners, LLC's current position in REGN?

As of Q3 2026, ARS Investment Partners, LLC holds 44.51K shares of REGN (REGENERON PHARMACEUTICALS), valued at $33.75M, representing 1.52% of its reported portfolio and ranking #19.

Has ARS Investment Partners, LLC been buying or selling REGN?

In the latest 13F filing (Q3 2026), ARS Investment Partners, LLC reduced its position in REGN. The position peaked in Q1 2026 at 45.27K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.